Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial.
OBJECTIVE
Symptoms of abacterial chronic prostatitis/chronic pelvic pain syndrome are considered to be associated with prostate inflammation. The ongoing Reduction by Dutasteride of Prostate Cancer Events trial is a 4-year, phase III, placebo controlled study to determine whether 0.5 mg dutasteride daily decreases the risk of biopsy detectable prostate cancer. All men underwent biopsy before study entry, allowing review of the relationship between histological prostate inflammation and prostatitis symptoms.


METHODS
Eligible men were 50 to 75 years old with serum prostate specific antigen 2.5 ng/ml or greater and 10 ng/ml or less (ages 50 to 60 years), or 3.0 ng/ml or greater and 10 ng/ml or less (older than 60 years), and an International Prostate Symptom Score of less than 25 (or less than 20 if already on alpha-blocker therapy). Acute prostatitis was an exclusion criterion. The National Institutes of Health Chronic Prostatitis Symptom Index was used to assess prostatitis-like symptoms. Spearman rank correlations were used to assess the relationship between acute and chronic inflammation, and Chronic Prostatitis Symptom Index scores for the pain, urinary symptoms and quality of life domains as well as average pain, total score and prostatitis-like symptoms.


RESULTS
Data were available on 5,597 patients. The distribution of inflammation status was similar for those with and without chronic prostatitis-like symptoms. Significant correlations were found between average chronic inflammation, and total Chronic Prostatitis Symptom Index score and subscores for urinary symptoms and quality of life but the magnitude of these correlations was small.


CONCLUSIONS
A lack of clinically meaningful association was found between prostatitis-like pain symptoms and histological inflammation in the Reduction by Dutasteride of Prostate Cancer Events population, suggesting that the view that symptoms of chronic prostatitis/chronic pelvic pain syndrome and prostate inflammation are associated needs further scrutiny.
Nickel
J Curtis
JC
Department of Urology, Queen's University, Kingston General Hospital, Kingston, Ontario, Canada. jcn@post.queensu.ca
Roehrborn
Claus G
CG
O'leary
Michael P
MP
Bostwick
David G
DG
Somerville
Matthew C
MC
Rittmaster
Roger S
RS
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000627:therapeutic use; D000368:Aged; D001378:Azasteroids / Q000627:therapeutic use; D001707:Biopsy, Needle; D002908:Chronic Disease; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation; D008297:Male; D008875:Middle Aged; D017699:Pelvic Pain / Q000150:complications; D011467:Prostate / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000517:prevention & control; D011472:Prostatitis / Q000150:complications / Q000175:diagnosis / Q000473:pathology*; D016032:Randomized Controlled Trials as Topic
D001378:Azasteroids; D004791:Enzyme Inhibitors; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase; D000068538:Dutasteride